1. A compound of the general formula (I):
wherein
Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine condensed with benzene; or (b) pyridine condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of pyridine ring constituting Ring A,
Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle,
Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle,
R1 is (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) optionally substituted phenyl; (f) halogen; or (g) nitrile,
R2a, R2b, R2c and R2d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) optionally substituted phenyl; (f) optionally substituted monocyclic aromatic heterocyclic group; (g) optionally substituted monocyclic non-aromatic heterocyclic group; (h) halogen; or (i) nitrile,
R3a, R3b, R3c and R3d are each independently (a) hydrogen; (b) optionally substituted alkyl; (c) optionally substituted cycloalkyl; (d) optionally substituted alkoxy; (e) optionally substituted cycloalkoxy; (f) optionally substituted phenyl; (g) optionally substituted monocyclic aromatic heterocyclic group; (h) optionally substituted monocyclic non-aromatic heterocyclic group; (i) optionally substituted phenoxy; (j) halogen; or (k) hydroxy, or
two substituent groups selected from R3a, R3b, R3c and R3d combine each other to form oxo,
R5 and R6 are each independently (a) hydrogen; (b) alkyl; (c) halogenoalkyl; (d) cycloalkyl; or (e) halogenocycloalkyl, or R5 and R6 combine each other at their terminals together with the adjacent carbon atom to form monocyclic alicyclic hydrocarbon,
n is 0, 1 or 2;
X is carboxy, alkoxycarbonyl, hydroxyalkyl, optionally substituted aminocarbonyl, or optionally substituted alkanoyl; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R1 is (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl, C1-C6 alkoxy, halogen, oxo and hydroxy; (c) C3-C7 cycloalkyl which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkyl, C1-C6 alkoxy and halogen; (d) C1-C6 alkoxy which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl, C1-C6 alkoxy, halogen and hydroxy; (e) phenyl which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (f) halogen; or (g) nitrile,
R2a, R2b, R2c and R2d are each independently (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkoxy, C3-C7 cycloalkyl, halogen, oxo and hydroxy; (c) C3-C7 cycloalkyl which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkyl, C1-C6 alkoxy and halogen; (d) C1-C6 alkoxy which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkoxy, C3-C7 cycloalkyl and halogen; (e) phenyl which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, Ci-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (f) 5 to 6-membered monocyclic aromatic heterocyclic group which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl. C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (g) 4 to 7-membered monocyclic non-aromatic heterocyclic group which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (h) halogen; or (i) nitrile,
R3a, R3b, R3c and R3d are each independently (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl (in which the cycloalkyl and halogenocycloalkyl may be each independently optionally substituted by 1 to 3 groups selected from C1-C6 alkyl and C1-C 6 halogenoalkyl), C1-C6 alkoxy, C1-C6 halogenoalkoxy, phenyl, 5 to 6-membered monocyclic aromatic heterocyclic group, 4 to 7-membered monocyclic non-aromatic heterocyclic group (in which the phenyl, aromatic heterocyclic group and non-aromatic heterocyclic group may be each independently optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen), halogen, oxo and hydroxy; (c) C3-C7 cycloalkyl which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy, halogen and hydroxy; (d) C1-C6 alkoxy which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl (in which the cycloalkyl and halogenocycloalkyl may be each independently optionally substituted by 1 to 3 groups selected from C1-C6 alkyl and C1-C6 halogenoalkyl), C1-C6 alkoxy, C1-C6 halogenoalkoxy, phenyl, 5 to 6-membered monocyclic aromatic heterocyclic group, 4 to 7-membered monocyclic non-aromatic heterocyclic group (in which the phenyl, aromatic heterocyclic group and non-aromatic heterocyclic group may be each independently optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen), halogen and hydroxy; (e) C3-C7 cycloalkoxy which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy, halogen and hydroxy; (f) phenyl which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (g) 5 to 6-membered monocyclic aromatic heterocyclic group which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (h) 4 to 7-membered monocyclic non-aromatic heterocyclic group which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (i) phenoxy which may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, C3-C7 cycloalkyl, C3-C7 halogenocycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy and halogen; (j) halogen; or (k) hydroxy, or two substituent groups selected from R3a, R3b, R3c and R3d combine each other to form oxo,
R5 and R6 are each independently (a) hydrogen; (b) C1-C6 alkyl; (c) C1-C6 halogenoalkyl; (d) C3-C7 cycloalkyl; or (e) C3-C7 halogenocycloalkyl, or R5 and R5 combine each other at their terminals together with the adjacent carbon atom to form 3 to 7-membered monocyclic alicyclic hydrocarbon,
X is (a) carboxy; (b) C1-C6 alkoxycarbonyl; (c) hydroxy-C1-C6 alkyl; (d) aminocarbonyl wherein a nitrogen atom may be optionally substituted by one group selected from C1-C6 alkyl, C1-C6 alkoxy and nitrite; or (e) C2-C7 alkanoyl which may be optionally substituted by 1 to 3 halogens, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2, wherein Ring A is quinoline, isoquinoline or pyrrolopyridine, or a pharmaceutically acceptable salt thereof.
4. The compound of claim 2, wherein Ring A, R1, R2a, R2b, R2c and R2d combine each other to form a group of the following formula:
wherein one of Y and Z is CR2d, and the other is a chemical bond, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4, wherein Ring C is benzene, and X is carboxy and binds to Ring C at 4-position to the aminosulfonyl moiety, or a pharmaceutically acceptable salt thereof.
6. The compound of claim 5, wherein Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; or (b) monocyclic or bicyclic aromatic heterocycle, and
n is 0 or 1, or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6, wherein a partial structure:
is a group of the following formula (A):
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 6, wherein a partial structure:
is a group of the following formula (B):
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 7 wherein R1 is (a) C1-C6 alkyl which may be optionally substituted by 1 to 7 halogens; (b) C3-C7 cycloalkyl; (c) alkoxy; or (d) halogen,
R2b and R2b are hydrogen,
R2b is (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 halogens; (c) C3-C7 cycloalkyl; or (d) C1-C6 alkoxy,
R3a and R3b are each independently (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl (in which the cycloalkyl may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl and C1-C6 halogenoalkyl), C1-C6 alkoxy, C1-C6 halogenoalkoxy, and halogen; (c) C3-C7 cycloalkyl which may be optionally substituted by 1 to 7 groups selected from C1-C6 alkyl, C1-C6 halogenoalkyl, and halogen; (d) C1-C6 alkoxy which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl, C1-C6 alkoxy, C1-C6 halogenoalkoxy, and halogen; or (e) halogen,
R3c and R3d are hydrogen,
R5 and R6 are hydrogen,
n is 1, or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1, which is selected from he group consisting of
4-({(4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)benzoic acid;
4-{3-fluoro-4-(trifluoromethoxy)benzyl(4-methylisoquinolin-3-yDaminosulfonyl}benzoic acid;
4-({(1-cyclopropyl-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)-benzoic acid;
4-{4-(1-ethoxy-2,2,2-trifluoro-1-methylethyl)benzyl(4-methylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-(3-methylquinolin-2-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)benzoic acid;
4-{4-fluoro-3-(trifluoromethyl)benzyl(3-methylisoquinolin-2-aminosulfonyl}benzoic acid;
4-{(4-t-butylbenzyl)(4-methylisoquinolin-3-aminosulfony}benzoic acid;
4-{4-(cyclopropylmethyl)benzyl}(4-methylisoquinolin-3-amino}sulfonyl}benzoic acid;
4-{R4-fluoro-3-(trifluoromethyl)benzyly4-methylisoquinolin-3-y0aminosulfonyl}benzoic acid;
4-{(4-methylisoquinolin-3-yl))2-naphthylmethy)aminosulfony}benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzyamino}sulfony)-benzoic acid:
4-({(4-chloroisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)benzoic acid;
4-((4-methylisoquinolin-3-yl)(5,6,7,8-tetrahydronaphthalen-2-ylmethy) aminosulfonyl}-benzoic acid;
4-{(2,3-dihydro-1H-inden-5-yl)methyl)(4-methylisoquinolin-3-yl)aminosulfony}benzoic acid:
4-{(1,1-dimethyl-2,3-dihydro-1H-inden-5-yl)methyl(4-methylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-{(2,2-dimethyl-2,3-dihydro-1H-inden-5-yl)mthyl4-methylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-{(3,3-dimethyl-2,3-dihydro-1-benzofuran-6-yl)methyl(4-methylisoquinolin-3-yl)aminosulfonyl}benzoic acid;
4-{(1-benzothiophen-2-yl)methyl(4-methylisoquinolin-3-yl)aminosulfonyl}benzoic acid;
4-({(1,4-dimethylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)benzoic acid; and
4-({(4-methylisoquinolin-3-yl)4-(2,2,2-trifluoro-1-methoxy-1-methylethyl)benzylamino}-sulfonyl benzoic acid; or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1, which is selected from the group consisting of 4-({(1-cyclopropyl-4-methylisoquino -y)4-(trifluoromethoxy)benzylamino}sulfonyl)-benzoic acid;
4-({(1-methoxy-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)-benzoic acid;
4-({(1-isopropyl-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl)-benzoic acid;
4-{{3-chloro-44cyclopropyl(difluoro)methylbenzyl}(4-methylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl) benzoic acid;
4-{{3-chloro-4-cyclopropyl(difluoro)methylbenzyl}(1-cyclopropyl-4-methylisoquinolin-3-yl)aminosulfonyl}benzoic acid;
4-{{44cyclopropyl(difluoro)methyl-3-fluorobenzyl}(4-methylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-({4-(trifluoromethoxy)benzyl4-(trifluoromethyl)isoquinolin-3-ylamino}sulfonyl)benzoic acid;
4-R(4-cyclopropylisoquinolin-3-yl){5-(trifluoromethyl)pyridin-2-ylmethyl}amino)sulfonyl-benzoic acid;
4-{{3-chloro-4-cyclopropyl(difluoro)methylbenzyl}(4-cyclopropylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-{{4-cyclopropyl(difluoro)methyl-3-fluorobenzyl}(4-cyclopropylisoquinolin-3-yl)amino-sulfonyl}benzoic acid;
4-({(4-cyclopropylisoquinolin-3-yl)5-(trifluoromethoxy)-2, 3-dihydro-1 H-inden-1-ylamino}sulfonyl)benzoic acid;
4-({{3-chloro-4-cyclopropyl(difluoro)methypenzyl}4-(trifluoromethyl)isoquinolin-3-yl-amino}sulfonyl)benzoic acid; and
4-({{4-cyclopropyl(difluoro)methyl-3-fluorobenzyl}4-(trifluoromethyl)isoquinolin-3-yl-amino}sulfonyl)benzoic acid; or
a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition, comprising as the active ingredient the compound of claim 1 or a pharmaceutically acceptable salt thereof.
13. The compound of claim 9, wherein Ring B is benzene or pyridine,
R1 is methyl, trifluoromethyl, isopropyl, cyclopropyl, or methoxy,
R3a and R3b are each independently (a) hydrogen; (b) C1-C6 alkyl which may be optionally substituted by 1 to 7 groups selected from C3-C7 cycloalkyl (in which the cycloalkyl may be optionally substituted by 1 to 3 groups selected from C1-C6 alkyl and C1-C6 halogenoalkyl), Ci-C6alkoxy, C1-C6 halogenoalkoxy, and halogen; (c) C3-C7 cycloalkyl; (d) C1-C6alkoxy which may be optionally substituted by 1 to 7 halogens; or (e) halogen, or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1, which is 4-({(1-cyclopropyl-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzyamino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1, which is 4-({(1-isopropyl-4-methylisoquinolin-3-yl)4-(trifluoromethoxy)benzyl}amino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1, which is 4-{{3-chloro-4-cyclopropyl(difluoro)methylbenzyl}(4-methylisoquinolin-3-yl)aminosulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1, which is 4-({(4-cyclopropylisoquinolin-3-yl)4-(trifluoromethoxy)benzylamino}sulfonyl) benzoic acid or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1, which is 4-{{3-chloro-4-cyclopropyl(difluoro)methylbenzyl}(1-cyclopropyl-4-methylisoquinolin-3-yl)amino}-sulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.
19. The compound of claim 1, which is 4-{{4-cyclopropyl(difluoro)methyl-3-fluorobenzyl}(4-methylisoquinolin-3-yl)aminosulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.
20. The compound of claim 1, which is 4-({4-(trifluoromethoxy)benzyl4-(trifluoromethyl)isoquinolin-3-ylamino}sulfonyl)benzoic acid or a pharmaceutically acceptable salt thereof.
21. The compound of claim 1, which is 4-((4-cyclopropylisoquinolin-3-yl){5-(trifluoromethyl)pyridin-2-ylmethyl}amino)sulfonylbenzoic acid or a pharmaceutically acceptable salt thereof.
22. The compound of claim 1, which is 4-{{4-cyclopropyl(difluoro)methyl-3-fluorobenzyl}(4-cyclopropylisoquinolin-3-yl)aminosulfonyl}benzoic acid or a pharmaceutically acceptable salt thereof.
23. A method for treating a disease or condition selected from chronic pain, cephalalgia, urologic disease, carcinoma, respiratory disease, gastrointestinal disease, psychiatric disease, neurological disease, and dermatosis, the method comprising administering to a subject an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
24. The method of claim 23, wherein the disease or condition is selected from chronic pain and urologic disease.
25. The method of claim 24, wherein the disease or condition is selected from neuropathic pain, nociceptive pain, and mixed pain.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A lens barrel comprising:
a lens holding frame holding a lens group; and
a rack gear provided in the lens holding frame for being moved along a longitudinal direction of a main shaft by a rotation of a lead screw, wherein,
the rack gear includes:
a first tooth abutting with a groove of the lead screw,
a second tooth adjoining the first tooth and being disposed at an interval which is a groove pitch of the lead screw, such that the second tooth does not abut with the groove of the lead screw, and
a flat abutting portion abutting with a crest of at least one ridge of the lead screw.
2. The lens barrel of claim 1, wherein, along the longitudinal direction of the main shaft, the first tooth, the second tooth, and the abutting portion are disposed in this order.
3. The lens barrel of claim 1, wherein the rack gear includes only one said first tooth.
4. The lens barrel of claim 1, wherein,
a plurality of guide holes are formed in the lens holding frame;
where the longitudinal direction of the main shaft defines a height direction, the first tooth is located at a height corresponding to a substantial center between a first guide hole and a second guide hole among the plurality of guide holes; and
the second tooth is located closer to an end than is the first tooth.
5. The lens barrel of claim 1, wherein,
a guide hole is provided in the lens holding frame, the guide hole being penetrated by the main shaft; and
a first guide hole is formed in the lens holding frame, the first guide hole being penetrated by a sub-shaft; and
in a cross section taken orthogonal to the longitudinal direction of the main shaft, a point of abutment between the rack gear and the lead screw, the main shaft, and the sub-shaft are disposed in this order.
6. The lens barrel of claim 5, further comprising
a rack spring provided on the lens holding frame for energizing the rack gear against the lead screw, wherein
along a direction which is orthogonal to a direction of a force generated by the rack spring between the rack gear and the lead screw and which is orthogonal to the longitudinal direction of the main shaft, the point of abutment between the rack gear and the lead screw, the main shaft, and the sub-shaft are disposed in this order.
7. The lens barrel of claim 1, wherein,
the main shaft has a circular cross section;
a cross section of the guide hole taken orthogonal to the longitudinal direction of the main shaft includes at least two linear portions; and
the main shaft is in contact with the two linear portions.
8. The lens barrel of claim 7, wherein,
a plurality of said guide holes are formed in the lens holding frame;
each of the plurality of guide holes includes at least two linear portions;
the two linear portions of each of the plurality of guide holes are in contact with the main shaft;
each of the plurality of guide holes includes a corner portion corresponding to the two linear portions; and
the respective corner portions of the plurality of guide holes are oriented in mutually different directions.
9. The lens barrel of claim 7, wherein a corner portion of the guide hole corresponding to the two linear portions is oriented in a direction of a force acting on the guide hole.
10. The lens barrel of claim 9, wherein,
two guide holes are formed in the lens holding frame; and
the respective corner portions of the two guide holes are oriented in directions which are 45\xb0 apart.
11. The lens barrel of claim 7, wherein the cross section of the guide hole is a triangle or a rectangle.
12. The lens barrel of claim 6, wherein two linear portions are provided at positions of the plurality of guide holes which receive reaction forces occurring in the lens holding frame when the rack spring energizes the rack gear against the lead screw.
13. The lens barrel of claim 12, wherein the two linear portions are energized against the main shaft due to the reaction forces.
14. The lens barrel of claim 9, wherein,
each of the plurality of guide holes includes a corner portion corresponding to the two linear portions; and
the corner portion of each of first and second guide holes is oriented in a direction of a force which the rack gear applies to the lead screw.
15. An imaging apparatus comprising the lens barrel of claim 1.